Suzanne Louise Bruhn
CIK 1517790 · last filed 2026-06-15
Suzanne Louise Bruhn is a corporate insider who has filed 60 SEC Form 4 insider transactions across 11 companies since 2011. The most recent filing, for DFTX, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$904.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.13M
11
60
-$904.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Director | 24,289 | $44.39 | $1.08M | $0 | 1 | 2026-06-15 |
| TVTX | Director | 32,750 | $62.76 | $2.06M | $0 | 6 | 2026-05-21 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | Director | 0 | $8.05 | $0 | $0 | 9 | 2025-08-05 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,623 | $15.00 | $294.3K | $0 | 4 | 2025-06-16 |
| PLRX | Director | — | $1.05 | — | $0 | 5 | 2025-06-09 |
| AVTX | Director | — | $18.84 | — | $0 | 1 | 2021-10-04 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | — | $2.93 | — | $0 | 8 | 2021-07-02 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 4 | 2020-06-10 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 5,250 | — | — | $0 | 1 | 2020-04-09 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 2 | 2018-08-13 |
| Raptor Pharmaceutical Corp (RPTP) Delisted | Director | 8,330 | — | — | -$904.6K | 19 | 2016-10-26 |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | DFTX | Grant (A) | +4,666 | $0 | EDGAR |
| 2026-05-21 | TVTX | Grant (A) | +4,000 | $0 | EDGAR |
| 2025-08-05 | Vigil Neuroscience, Inc. (VIGL) Delisted | Disp (D) | −5,000 | $0 | EDGAR |
| 2025-06-16 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | PLRX | Grant (A) | — | $0 | EDGAR |
| 2025-05-23 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2025-05-16 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2025-03-04 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | PLRX | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.